每經AI快訊，九典制藥(yao)（SZ 300705，收(shou)盤(pan)價：22.84元）8月15日晚間發布公(gong)(gong)(gong)告(gao)稱，持(chi)(chi)有公(gong)(gong)(gong)司股(gu)(gu)份(fen)約(yue)63萬(wan)股(gu)(gu)（占(zhan)公(gong)(gong)(gong)司總股(gu)(gu)本(ben)(ben)(ben)比(bi)(bi)(bi)例(li)(li)為0.129%）的(de)監(jian)事(shi)段斌女士(shi)，計劃(hua)在本(ben)(ben)(ben)公(gong)(gong)(gong)告(gao)披露(lu)之日起(qi)15個交(jiao)易日后的(de)3個月內以集(ji)(ji)中(zhong)競(jing)價方式減持(chi)(chi)公(gong)(gong)(gong)司股(gu)(gu)份(fen)不(bu)超過約(yue)16萬(wan)股(gu)(gu)（占(zhan)公(gong)(gong)(gong)司總股(gu)(gu)本(ben)(ben)(ben)比(bi)(bi)(bi)例(li)(li)為0.032%）。持(chi)(chi)有公(gong)(gong)(gong)司股(gu)(gu)份(fen)約(yue)15萬(wan)股(gu)(gu)（占(zhan)公(gong)(gong)(gong)司總股(gu)(gu)本(ben)(ben)(ben)比(bi)(bi)(bi)例(li)(li)為0.03%）的(de)監(jian)事(shi)梁(liang)勝(sheng)華女士(shi)，計劃(hua)在本(ben)(ben)(ben)公(gong)(gong)(gong)告(gao)披露(lu)之日起(qi)15個交(jiao)易日后的(de)3個月內以集(ji)(ji)中(zhong)競(jing)價方式減持(chi)(chi)公(gong)(gong)(gong)司股(gu)(gu)份(fen)不(bu)超過約(yue)3.64萬(wan)股(gu)(gu)（占(zhan)公(gong)(gong)(gong)司總股(gu)(gu)本(ben)(ben)(ben)比(bi)(bi)(bi)例(li)(li)為0.007%）。

2023年(nian)1至12月份，九典制藥(yao)的營(ying)業(ye)收入構成(cheng)為：藥(yao)品制劑(ji)占(zhan)(zhan)(zhan)比(bi)83.06%，藥(yao)用輔料占(zhan)(zhan)(zhan)比(bi)6.53%，原料藥(yao)占(zhan)(zhan)(zhan)比(bi)6.23%，植物(wu)提取(qu)物(wu)及(ji)其他(ta)占(zhan)(zhan)(zhan)比(bi)2.72%，技術轉讓及(ji)服務占(zhan)(zhan)(zhan)比(bi)1.41%。

截至發稿，九(jiu)典制藥市值為111億元(yuan)。

道(dao)達號（daoda1997）“個股趨勢”提醒：
1. 九典制藥近30日內北向資金持股量增加36.95萬股，占流通股比例增加0.13%；
2. 近30日內共有2批機構對九典制藥調研，合計調研的機構家數為8家；
3. 九典制(zhi)藥上次發(fa)布(bu)(bu)減持(chi)公(gong)告是2023年10月16日，第二個交(jiao)易日下跌1.47%，九典制(zhi)藥近一年共發(fa)布(bu)(bu)2次減持(chi)類(lei)公(gong)告。

每經頭條（nbdtoutiao）——

(記者 曾健輝)

免責聲(sheng)明(ming)：本文內容與數據(ju)僅供參考，不構成(cheng)投資建議，使用(yong)前請核實。據(ju)此(ci)操作，風險自擔(dan)。